Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics, Onsite Women's Health Partner to ID Women With High Breast Cancer Risk

NEW YORK – Myriad Genetics announced Tuesday that it has partnered with breast health services company Onsite Women's Health to launch a national breast cancer risk assessment program.

The collaboration aims to screen and identify younger women with higher breast cancer risk from among the over 400,000 patients that Onsite serves nationwide. The two firms will leverage Myriad's MyRisk and RiskScore hereditary breast cancer and risk assessment tools, and Onsite's expertise in breast health services, which include mammography and ultrasound.

Myriad and Onsite plan to offer the program to one-third of Onsite's Ob/Gyn and primary care physician partnerships over the next few months, with further expansion expected in 2024.

"Our collaboration with Onsite makes it easy to access genetic testing and breast cancer risk assessment at the point of care for the roughly 25 percent of women who are eligible for testing," Paul Diaz, president and CEO of Myriad Genetics, said in a statement. "This program can help identify more high-risk patients and guide personalized medical management plans for breast cancer risk reduction and early detection strategies."

Myriad also recently partnered with SimonMed Imaging to expand its hereditary cancer assessment reach and has been active in improving its RiskScore through the addition of polygenic risk scores combined with clinical features.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.